retatrutide glp-1 gip glucagon triple agonist phase 2 results vs. Ozempic: The That May Change Will Retatrutide Replace Tirzepatide

Berkovic MC, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A

2023, Harvard Health Publishing

About a year ago, Canciello, a Medicaid recipient, started taking the GLP-1 drug Zepbound

Because insurance companies view diabetes as an illness, they often cover GLP-agonists to treat it

A: According to ro.co (pricing as of November 2025), costs include two components: Membership Fees (separate from medication): First month: $45 Subsequent months: $145/month recurring Medication Costs (separate from membership, varies): Zepbound vials (LillyDirect): $349-$499/month Wegovy pens (NovoCare): $499/month Zepbound pens: ~$1,050/month Ozempic: Varies by pharmacy Insurance copay: $25-$300+ (if approved

There is no diet history, no exercise history, no blood pressure capture, no labs upload, and no government-ID verification